» Articles » PMID: 33868229

Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes

Overview
Journal Front Immunol
Date 2021 Apr 19
PMID 33868229
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Due to its richness in antigen presenting cells, e.g., dendritic cells (DC), the skin has been identified as a promising route for immunotherapy and vaccination. Several years ago, a skin delivery system was developed based on epicutaneous patches allowing the administration of antigen through intact skin. Using mouse models, we have shown that epicutaneous allergen application leads to a rapid uptake and transport of allergen-positive cells to skin-draining lymph nodes (LN). This occurred primarily in animals previously sensitized to the same allergen. In that context, we sought to better understand the role of the specific preexisting immunity in allergen capture by skin DC and their subsequent migration to LN. Specifically, we investigated the role of humoral immunity induced by sensitization and the involvement of IgG Fc receptors (FcγR). Epicutaneous patches containing fluorescently-labeled ovalbumin (OVA) were applied to naïve mice that had previously received either sera or purified IgG isolated from OVA-sensitized mice. To investigate the involvement of FcγR, animals received 2.4G2 (anti-FcγRII/RIII) blocking antibody, 24 hours before patch application. Mice that received sera or purified IgG originating from OVA-sensitized mice showed an increase in the quantity of OVA-positive DC in skin and LN. Moreover, the blockade of FcγR reduced the number of OVA-positive DC in LN to a level similar to that observed in naïve animals. Overall, these results demonstrate that preexisting specific-IgG antibodies are involved in allergen capture by skin DC following EPIT through the involvement of antigen-specific IgG-FcγR.

Citing Articles

Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.

Shah S, Oakes R, Jewell C Adv Drug Deliv Rev. 2024; 209:115315.

PMID: 38670230 PMC: 11111363. DOI: 10.1016/j.addr.2024.115315.


Recent advances in epicutaneous immunotherapy and potential applications in food allergy.

Herve P, Dioszeghy V, Matthews K, Bee K, Campbell D, Sampson H Front Allergy. 2023; 4:1290003.

PMID: 37965375 PMC: 10641725. DOI: 10.3389/falgy.2023.1290003.

References
1.
Campana R, Moritz K, Neubauer A, Huber H, Henning R, Brodie T . Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients. Sci Rep. 2017; 7(1):11657. PMC: 5599525. DOI: 10.1038/s41598-017-10278-1. View

2.
Hayashi S, Matsuda H, Okumura K, Ra C . Mouse Langerhans cells do not express the high-affinity receptor for IgE. Arch Dermatol Res. 1999; 291(4):241-3. DOI: 10.1007/s004030050401. View

3.
Clatworthy M, Petrie Aronin C, Mathews R, Morgan N, Smith K, Germain R . Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat Med. 2014; 20(12):1458-63. PMC: 4283039. DOI: 10.1038/nm.3709. View

4.
Crowe Jr J . Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis. 2001; 33(10):1720-7. DOI: 10.1086/322971. View

5.
Mondoulet L, Dioszeghy V, Puteaux E, Ligouis M, Dhelft V, Plaquet C . Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model. J Allergy Clin Immunol. 2015; 135(6):1546-57.e4. DOI: 10.1016/j.jaci.2014.11.028. View